Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Norman Atkins"'
Autor:
Diana T. Amari, Timothy Juday, Feride H. Frech, Weiying Wang, Zheng Wu, Norman Atkins, Emerson M. Wickwire
Publikováno v:
BMC Geriatrics, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background Falls are the leading cause of injury-related death among older Americans. While some research has found that insomnia heightens falls, health care resource utilization (HCRU) and costs, the impact of insomnia treatments on fall r
Externí odkaz:
https://doaj.org/article/ebab02f41da14982bd0386163e35d469
Autor:
Norman Atkins, Jennifer W Mitchell, Elena V Romanova, Daniel J Morgan, Tara P Cominski, Jennifer L Ecker, John E Pintar, Jonathan V Sweedler, Martha U Gillette
Publikováno v:
PLoS ONE, Vol 5, Iss 9, p e12612 (2010)
Neuropeptides are critical integrative elements within the central circadian clock in the suprachiasmatic nucleus (SCN), where they mediate both cell-to-cell synchronization and phase adjustments that cause light entrainment. Forward peptidomics iden
Externí odkaz:
https://doaj.org/article/8515168685af43119a81d63505f81d0d
Autor:
Thomas Roth, Russell Rosenberg, Charles M. Morin, Jane Yardley, Kate Pinner, Carlos Perdomo, Norman Atkins, Elizabeth Pappadopulos, Manoj Malhotra, Margaret Moline
Publikováno v:
Sleep Medicine. 90:249-257
Evaluate changes in insomnia severity in subjects with moderate to severe insomnia (Insomnia Severity Index [ISI] score ≥15) treated for 12 months nightly with lemborexant.This phase 3 randomized study comprised two 6-month treatment periods. In Pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4242b783bee9b0600cba6a9e3f64a46
https://doi.org/10.1016/j.sleep.2022.01.024
https://doi.org/10.1016/j.sleep.2022.01.024
Autor:
Diana T. Amari, Timothy R. Juday, Feride H. Frech, Weiying Wang, Deval Gor, Norman Atkins, Emerson M. Wickwire
Publikováno v:
Advances in Therapy. 39:1324-1340
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4413e6c04c7755812f87bd6ebf730eb1
https://doi.org/10.1007/s12325-022-02041-4
https://doi.org/10.1007/s12325-022-02041-4
Autor:
Craig Chepke, Rakesh Jain, Russell Rosenberg, Margaret Moline, Jane Yardley, Kate Pinner, Dinesh Kumar, Carlos Perdomo, Gleb Filippov, Norman Atkins, Manoj Malhotra
Publikováno v:
Postgraduate medicine. 134(3)
Fatigue is a common symptom in patients with insomnia. This analysis evaluated whether treatment of nighttime symptoms of insomnia with a dual orexin receptor antagonist, lemborexant, might also reduce fatigue.Analyses were conducted of two phase 3 s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e812537c5af84e9ca1837457059acc7a
https://pubmed.ncbi.nlm.nih.gov/35254948
https://pubmed.ncbi.nlm.nih.gov/35254948
Autor:
Diana T, Amari, Timothy R, Juday, Feride H, Frech, Weiying, Wang, Deval, Gor, Norman, Atkins, Emerson M, Wickwire
Publikováno v:
Advances in therapy. 39(3)
Falls are a common cause for morbidity and mortality among patients taking prescription insomnia medication. The objective of this study is to compare the risk of falls, all-cause healthcare resource utilization (HCRU), and costs among patients treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2a64a90ab6ea9a3aadc1b3b0c9b2de0f
https://pubmed.ncbi.nlm.nih.gov/35072889
https://pubmed.ncbi.nlm.nih.gov/35072889
Publikováno v:
The Journal of Clinical Psychiatry. 82
Objective: To describe lemborexant for the treatment of insomnia (DSM-5) in adults using number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH). Methods: Lemborexant data were obtained from two Phase 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e104cdd0dabb17047756f40140a16ade
https://doi.org/10.4088/jcp.20m13795
https://doi.org/10.4088/jcp.20m13795
Autor:
Manoj Malhotra, Dinesh Kumar, Maha Ahmad, Carlos Perdomo, Jess Amchin, Margaret Moline, Norman Atkins
Publikováno v:
Sleep. 44:A134-A135
Introduction Dosing paradigms for transitioning patients to lemborexant (LEM) from zolpidem (ZOL: immediate [IR] or extended-release [ER]) were examined in E2006-A001-312 (Study 312; NCT04009577), an open-label pilot study. Given insomnia prevalence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ceef6121191a29de4008d6799bac865b
https://doi.org/10.1093/sleep/zsab072.336
https://doi.org/10.1093/sleep/zsab072.336
Autor:
Jane Yardley, Rakesh Jain, Craig Chepke, Manoj Malhotra, Norman Atkins, Margaret Moline, Kate Pinner
Publikováno v:
The American Journal of Geriatric Psychiatry. 29:S125-S126
Introduction In addition to sleep onset and/or maintenance difficulties, sleep-related daytime impairments must be acknowledged by patients to meet DSM-5 insomnia disorder diagnostic criteria. Daytime functioning impairments of insomnia disorder may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4315032baa1dce45b1c46d91efc2056
https://doi.org/10.1016/j.jagp.2021.01.121
https://doi.org/10.1016/j.jagp.2021.01.121
Autor:
Norman Atkins, Margaret Moline, Kate Pinner, Carlos Perdomo, Gary Zammit, Jane Yardley, Russell Rosenberg
Publikováno v:
CNS Spectrums. 25:304-305
Study Objective(s):The dual orexin receptor antagonist, lemborexant (LEM), is being investigated for the treatment of insomnia disorder. Drugs targeting the orexin system, like LEM, may decrease wakefulness and promote sleep with fewer potential adve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2eacbbb7e8fa118eb51faf342cbed33a
https://doi.org/10.1017/s1092852920000802
https://doi.org/10.1017/s1092852920000802